Science & Evidence

Research & Publications

Peer-reviewed studies on Akkermansia muciniphila PROBIO (strain CGMCC No.20955), spanning weight management, gut barrier integrity, metabolic health, immune support, safety, and more.

13peer-reviewed publications
7clinical studies
130subjects in human RCT
8+health areas studied

Featured human clinical trial

130-subject, 8-week randomized controlled trial

A 2025 randomized, double-blind, placebo-controlled trial in overweight adults reported that both live and pasteurized AKK PROBIO® were associated with statistically significant reductions in body weight, BMI, and body fat percentage over 8 weeks. The study also observed improvements in liver function markers, blood lipid profiles, emotional well-being scores, and gut microbiota composition.

View full text

Safety research

Characterization and toxicology support

Published safety materials include strain characterization, preliminary safety evaluation, genotoxicity context, and subchronic toxicity evidence. These materials support technical, regulatory, and QA review.

View safety characterization

Mechanism research

Gut barrier, SCFA, GLP-1, immune, uric acid, PCOS, and neuroinflammation models

Preclinical studies provide mechanism context across gut barrier integrity, metabolic health, immune modulation, uric acid metabolism, reproductive health, and neurological research. These studies help technical teams understand biological pathways and application fit.

Evidence is provided for B2B ingredient evaluation, not as finished-product disease claims.

AKK PROBIO research and documentation materials collage

Evidence materials

Study materials for R&D, regulatory, and QA review

AKK PROBIO® evidence materials bring together human clinical research, safety characterization, mechanism studies, and preclinical research in one technical review pathway.

Publication index

Strain-specific citation map

AKK PROBIO® strain-specific evidence includes 13 peer-reviewed publications, 7 clinical studies, and 18 strain-specific patents. The index below gives technical teams direct research anchors for evaluation.

Human RCT

Akkermansia muciniphila PROBIO ameliorates overweight via gut microbiota modulation: a randomized controlled trial

Food Science and Human Wellness, 2025. Human RCT, 130 subjects, 8-week, double-blind, placebo-controlled. DOI: 10.26599/FSHW.2025.9250659.

View full text
Gut barrier

Inactivated Akkermansia muciniphila AKK PROBIO Preserves Intestinal Homeostasis and Ameliorates DSS-Induced Colitis in Mice

Foods, 2025. Animal study. PMID: 41376001. DOI: 10.3390/foods14234063.

View PubMed record
Metabolic health

Pasteurized Akkermansia muciniphila AKK PROBIO Attenuates Obesity Through Gut Microbiota-SCFA-GLP-1 Axis

Probiotics and Antimicrobial Proteins, 2026. Animal study. PMID: 41123834. DOI: 10.1007/s12602-025-10805-x.

View DOI
Immune support

Heat-inactivated Akkermansia muciniphila AKK-PROBIO ameliorates cyclophosphamide-induced immunosuppression

Anaerobe, 2026. Animal study. PMID: 41297661. DOI: 10.1016/j.anaerobe.2025.103016.

View DOI
Safety

Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO

Foods, 2024. Characterization and safety evaluation. Full text available through PMC.

View full text
Reproductive health

Akkermansia muciniphila PROBIO therapy promotes arginine biosynthesis and reverses reproductive impairments in PCOS rats

Frontiers of Medicine, 2025. Animal study. DOI: 10.1007/s11684-025-1161-3.

View DOI
Uric acid

Research on preventive effect of Akkermansia muciniphila AKK PROBIO on acute gouty arthritis in mice

Food Science & Nutrition, 2024. Animal study. PMID: 39479687. DOI: 10.1002/fsn3.4367.

View PubMed record
Safety

Lack of genotoxicity and subchronic toxicity in safety assessment studies of Akkermansia muciniphila formulation

Toxicology Reports, 2024. Species-level safety evidence. PMID: 39554606. DOI: 10.1016/j.toxrep.2024.101790.

View DOI
Neuroinflammation

Akkermansia muciniphila reduces neuroinflammation and Aβ deposition via tryptophan metabolism

Alzheimer's Research & Therapy, 2026. Animal study. PMID: 41715194. DOI: 10.1186/s13195-025-01880-x.

View PubMed record

Is there human clinical trial data for AKK PROBIO?

Yes. A 2025 randomized, double-blind, placebo-controlled trial enrolled 130 overweight adults and studied both live and pasteurized AKK PROBIO® over 8 weeks.

What health areas has AKK PROBIO been studied in?

Published research spans weight management, gut barrier integrity, metabolic health, immune modulation, uric acid metabolism, reproductive health, neuroinflammation, and safety/toxicology.

Request the complete clinical and technical dossier

Technical teams can request study summaries, citation references, safety materials, regulatory documents, and application-specific documentation.

Request a sample & technical dossier

Need samples, specs, or regulatory documents?

Share your technical, regulatory, or commercial needs and our team will connect you with the right materials.

Request a Sample